NHS Approves First Daily Pill for Endometriosis Treatment in England

The National Institute for Health and Care Excellence (NICE) has approved the first daily oral treatment for endometriosis on the NHS in England. The medication, known as Ryeqo (relugolix-estradiol-norethisterone acetate), will be available for patients who have exhausted all other treatment options.

Endometriosis is a chronic condition affecting around 1.5 million women in the UK. It occurs when tissue similar to the womb lining grows in other areas of the body, leading to severe pain, heavy menstrual bleeding, fatigue, and fertility challenges.

Ryeqo works by suppressing the hormones that contribute to endometriosis symptoms while including hormone replacement to manage potential side effects. Unlike injectable treatments, this once-daily tablet offers a more convenient option, allowing patients to take control of their condition without frequent medical visits.

Helen Knight, director of medicines evaluation at NICE, described the approval as a significant step in managing endometriosis. She emphasized that the treatment provides patients with an alternative that is both effective and manageable, particularly for those considering pregnancy or seeking to minimize side effects.

The list price of Ryeqo for a 28-day supply is set at £72 (excluding VAT). The approval follows additional evidence provided by the manufacturer, Gedeon Richter, addressing concerns about the drug’s long-term effectiveness and cost efficiency.

Despite the breakthrough, access to the medication will be limited, as only around 1,000 women per year in England are expected to qualify under the current guidelines. Endometriosis UK welcomed the new treatment but highlighted the need for broader options to support the many women still struggling with the condition.

The approval of Ryeqo represents a major advancement in endometriosis care, offering patients a new option where previous treatments have failed. However, campaigners continue to call for further investment in research and wider treatment accessibility for those affected by the condition.